Revvity (NYSE:RVTY) Issues Earnings Results

Revvity (NYSE:RVTY) announced its earnings results on Friday. The company reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.05, RTT News reports. Revvity had a net margin of 9.34% and a return on equity of 7.42%. During the same quarter in the previous year, the firm posted $1.25 EPS. Revvity updated its FY 2025 guidance to 4.900-5.000 EPS.

Revvity Price Performance

RVTY traded down $0.65 on Friday, hitting $126.19. 547,038 shares of the company were exchanged, compared to its average volume of 874,558. The business’s fifty day moving average is $116.60 and its 200 day moving average is $118.60. The firm has a market capitalization of $15.36 billion, a P/E ratio of 61.02, a price-to-earnings-growth ratio of 4.09 and a beta of 1.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.97 and a current ratio of 3.56. Revvity has a fifty-two week low of $97.32 and a fifty-two week high of $129.50.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.22%. The ex-dividend date is Thursday, April 17th. Revvity’s dividend payout ratio (DPR) is currently 13.53%.

Revvity announced that its board has approved a share repurchase program on Monday, November 4th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 6.5% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other Revvity news, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total transaction of $641,520.52. Following the sale, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

RVTY has been the topic of several research analyst reports. Raymond James reduced their price objective on shares of Revvity from $146.00 to $140.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. TD Cowen raised their price target on Revvity from $141.00 to $144.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Robert W. Baird increased their target price on Revvity from $136.00 to $138.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Leerink Partners lifted their target price on Revvity from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, Barclays reduced their price target on shares of Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a research report on Monday, November 25th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $132.00.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.